{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699996121626240.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/s0140-6736(05)17701-0"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0140673605177010?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0140673605177010?httpAccept=text/plain"}}],"dc:title":[{"@value":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699996121626245","@type":"Researcher","foaf:name":[{"@value":"Harry LA Janssen"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626114","@type":"Researcher","foaf:name":[{"@value":"Monika van Zonneveld"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626243","@type":"Researcher","foaf:name":[{"@value":"Hakan Senturk"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626249","@type":"Researcher","foaf:name":[{"@value":"Stefan Zeuzem"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626248","@type":"Researcher","foaf:name":[{"@value":"Ulus S Akarca"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626244","@type":"Researcher","foaf:name":[{"@value":"Yilmaz Cakaloglu"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626241","@type":"Researcher","foaf:name":[{"@value":"Christopher Simon"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626242","@type":"Researcher","foaf:name":[{"@value":"Thomas MK So"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626112","@type":"Researcher","foaf:name":[{"@value":"Guido Gerken"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626250","@type":"Researcher","foaf:name":[{"@value":"Robert A de Man"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626246","@type":"Researcher","foaf:name":[{"@value":"Hubert GM Niesters"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626113","@type":"Researcher","foaf:name":[{"@value":"Pieter Zondervan"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626247","@type":"Researcher","foaf:name":[{"@value":"Bettina Hansen"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996121626240","@type":"Researcher","foaf:name":[{"@value":"Solko W Schalm"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"01406736"}],"prism:publicationName":[{"@value":"The Lancet"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2005-01","prism:volume":"365","prism:number":"9454","prism:startingPage":"123","prism:endingPage":"129"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0140673605177010?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0140673605177010?httpAccept=text/plain"}],"createdAt":"2005-01-08","modifiedAt":"2020-04-05","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004232067135360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232550879360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004234473604352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Identification of Novel Recombinant Forms of Hepatitis B Virus Generated from Genotypes Ae and G in HIV-1-Positive Japanese Men Who Have Sex with Men"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235963698176","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360005516525941632","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Impact of Rapid Evolution of Hepatitis Viruses"}]},{"@id":"https://cir.nii.ac.jp/crid/1360022305560636288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Understanding hepatitis B virus dynamics and the antiviral effect of interferon-α treatment in humanized chimeric mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693322536960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum hepatitis B core‐related antigen as a treatment predictor of pegylated interferon in patients with <scp>HB</scp>eAg‐positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236945920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706238094848","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Virological and Clinical Characteristics of Hepatitis B Virus Genotype A"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709456608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360286995454329216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The antiviral effects of human microRNA miR‐302c‐3p against hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140804864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of peginterferon alpha‐2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567183036660352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevalence and epidemiological traits of HIV infections in populations with high-risk behaviours as revealed by genetic analysis of HBV"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232420830080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656190200320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848657210934016","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848657213536896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848663203172224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of a cell-based assay to identify hepatitis B virus entry inhibitors targeting the sodium taurocholate cotransporting polypeptide"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664425007744","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861707377081472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814738709120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204795197696","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of chronic hepatitis B which achieved hepatitis B surface antigen seroclearance during combination therapy with peginterferon alfa-2b and entecavir"},{"@language":"ja","@value":"エンテカビル・ペグインターフェロンα－２ｂ併用４８週治療にてＨＢｓ抗原が消失したＢ型慢性肝炎の１例"},{"@value":"症例報告 エンテカビル・ペグインターフェロンα-2b併用48週治療にてHBs抗原が消失したB型慢性肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク エンテカビル ・ ペグインターフェロンa-2b ヘイヨウ 48シュウ チリョウ ニテ HBs コウゲン ガ ショウシツ シタ Bガタ マンセイ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205746563840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Recent Advances in Hepatitis B Research"},{"@language":"ja","@value":"わが国におけるB型肝炎研究の最近の動向"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770184960","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Three cases of chronic hepatitis B in that interferon therapy was indicated"},{"@value":"インターフェロン治療を行ったB型慢性肝炎の3例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク インターフェロン チリョウ オ オコナッタ Bガタ マンセイ カンエン ノ 3レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681218742528","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/s0140-6736(05)17701-0"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1128/aac.00725-17_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.25348_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.42_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1016/j.jiac.2014.12.003_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1016/j.cmi.2016.12.014_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1101/2020.07.28.224840_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1111/liv.13046_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0742-5_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1007/s00535-017-1367-5_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1089/jir.2014.0234_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1111/apt.15197_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.7883/yoken.65.476_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.853_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1016/b978-0-12-374153-0.00015-1_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1128/jvi.00492-20_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1002/jmv.23564_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1017/s0950268812003123_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.3390/v14112468_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0645-5_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.3390/ijms19071940_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1016/j.virusres.2012.10.027_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.14789/pjmj.55.443_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1111/hepr.13768_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1007/s00535-023-02070-y_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2013.06.029_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"},{"@type":"CROSSREF","@value":"10.1089/aid.2014.0281_references_DOI_1QgIFUtXURa1A0m1POVkccfWjPZ"}]}